LivaNova PLC (NASDAQ:LIVN) Shares Purchased by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 1.4% in the fourth quarter, Holdings Channel reports. The firm owned 73,845 shares of the company’s stock after buying an additional 1,049 shares during the quarter. Wedge Capital Management L L P NC’s holdings in LivaNova were worth $3,821,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. acquired a new stake in shares of LivaNova in the 3rd quarter worth $7,932,000. Kingdon Capital Management L.L.C. acquired a new stake in shares of LivaNova in the 3rd quarter worth $7,123,000. Vanguard Group Inc. lifted its stake in shares of LivaNova by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock worth $93,612,000 after acquiring an additional 100,133 shares during the period. Barclays PLC lifted its stake in shares of LivaNova by 15.9% in the 3rd quarter. Barclays PLC now owns 851,870 shares of the company’s stock worth $45,047,000 after acquiring an additional 116,842 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of LivaNova in the 3rd quarter worth $1,672,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

NASDAQ:LIVN opened at $55.94 on Thursday. The company has a market capitalization of $3.02 billion, a P/E ratio of 174.82 and a beta of 0.89. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $59.86. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $53.92 and a two-hundred day moving average price of $50.59.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. The business had revenue of $310.10 million during the quarter, compared to the consensus estimate of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.81 earnings per share. As a group, research analysts expect that LivaNova PLC will post 3.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LIVN. Mizuho restated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a research note on Wednesday, March 27th. Barclays raised their target price on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Robert W. Baird raised their price objective on shares of LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a research note on Thursday, February 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $72.00 price objective on shares of LivaNova in a research note on Wednesday, March 20th. Finally, StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $64.40.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.